Debbie Rigby rounds up the latest in research news
Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the TGA amended the indication to restrict use in BPSD to patients with Alzheimer’s dementia for a maximum 12-week duration. The TGA labelling changes were associated with a significant reduction in the rate and duration of use of risperidone for BPSD in veterans living in both the aged care and community settings, and in the general older Australian population.
NSAIDs are the leading cause of hypersensitivity drug reactions, including rhinitis, asthma, rhinosinusitis, nasal polyposis, urticaria and/or angioedema, and anaphylaxis. This article provides information on identification, cross-tolerance and management of NSAID-induced hypersensitivity drug reactions.
Journal of Asthma and Allergy 2019;12:217–233.
Data from 68 Australian residential aged care facilities shows high use of NSAID use among residents. Nearly one-quarter of 10,367 residents used at least one NSAID. A majority of oral NSAID users concomitantly used a PPI. Among residents with any oral NSAID use, 182/1088 (16.7%) had triple whammy medication use.
Pharmacoepidemiology & Drug Safety, first published 6 August 2019.
Data from Canada shows peole with OA have a higher risk of developing CVD comapred to people without OA. Approximately 41% of the total effect of OA on increased CVD risk was mediated through NSAID use. The proportion mediated through NSAID was 23%, 56% and 64% for CHF, IHD and stroke, respectively.
Arthritis & Rheumatology, first published 6 August 2019.